News and press releases

  • Fraunhofer IZI and Nomad Bioscience extend and broaden collaboration

    Press release of Nomad Bioscience GmbH / January 11, 2022

    The Fraunhofer Institute for Cell Therapy and Immunology IZI and Nomad Bioscience GmbH have extended and expanded their collaboration. In July 2020, both had concluded an initial research and development agreement. The Fraunhofer IZI Molecular Drug Biochemistry and Therapeutics Development Branch in Halle (Saale) supports the Munich-based company in the identification and preclinical development of pharmaceutical product candidates, in particular through assay development, pharmacological and toxicological studies, and the development of preclinical models.

    more info
  • Outstanding bachelor thesis awarded

    News / November 26, 2021

    Lukas Nöltner, a student at Biberach University of Applied Sciences, was honored for his bachelor's thesis on "Characterization of monoclonal antibodies against the HERV Fc1 envelope protein", which was written at the Fraunhofer Institute for Cell Therapy and Immunology IZI. Biberach University of Applied Sciences honors students for outstanding achievements twice a year. The 500 euro prize in the field of pharmaceutical biotechnology was sponsored by the company Boehringer Ingelheim.

    more info
  • Researchers at the Fraunhofer Institute for Cell Therapy and Immunology are working on developing a tissue that can be used to filter and inactivate airborne pathogens. On November 11, 2021, the project team from Leipzig received a funding commitment from the Else Kröner-Fresenius Stiftung (EKFS) for the "Aerocatch" project.

    more info
  • View of the algae strain collection at Anhalt University of Applied Sciences.
    © Algae team at Anhalt University of Applied Sciences.

    Are algae the superfood and active ingredient suppliers of the future? Under the direction of Professor Carola Griehl, researchers at the Competence Center Algal Biotechnology at Anhalt University of Applied Sciences have been working on this question for many years. On May 27, 2021 the Anhalt University of Applied Sciences and the Fraunhofer Institute for Cell Therapy and Immunology IZI open the Center for Natural Product-Based Therapeutics (ZNT). In addition to the invited guests on site, all interested parties are invited via live stream to the ceremonial opening.

    more info
  • Schematic representation of monitoring CAR T cell therapies by flow cytometry
    © Fraunhofer IZI

    CAR T-cell therapy, a novel cancer immunotherapy, uses patients' own T cells, which have been genetically engineered, for treatment. Currently, this therapy is used for some forms of blood cancer and lymphoma. In order to assess both the success and side effects of CAR T-cell therapies, intensive monitoring after administration is necessary.

    more info
  • Frank-Holm Rögner of Fraunhofer FEP, Martin Thoma of Fraunhofer IPA, and PD Dr. Sebastian Ulbert and Dr. Jasmin Fertey of Fraunhofer IZI (from left to right) are awarded the Fraunhofer Prize "Technology for People and their Environment" 2021 for a more efficient, faster and environmentally friendly manufacturing process for vaccines.
    © Fraunhofer / Piotr Banczerowski

    Vaccines are currently a great source of hope for many people, as it is believed they will help to protect society against COVID-19 and pave the way back to a normal life. The current focus is clearly on coronavirus — but vaccines are also fundamental to combating other pathogens. A team of researchers from three Fraunhofer Institutes has now developed a method of producing vaccines that is faster, more efficient and more environmentally friendly than the conventional production process — and their efforts have earned them the Fraunhofer Prize for “Human- and Environment-Centered Technology”. The award ceremony took place during the annual conference of the Fraunhofer-Gesellschaft on May 5, 2021.

    more info
  • Periodontitis: Researchers search for a new active substance

    Press release of the Martin Luther University Halle-Wittenberg / March 03, 2021

    Targeted, efficient and with few side effects: A new method for combating periodontitis could render the use of broad-spectrum antibiotics superfluous. It was developed and tested for the first time by a team from Martin Luther University Halle-Wittenberg (MLU), the Fraunhofer Institute for Cell Therapy and Immunology IZI and Periotrap Pharmaceuticals GmbH, a Fraunhofer IZI spin-off. The aim is to neutralise only bacteria that cause periodontitis while sparing harmless bacteria. The study appeared in the "Journal of Biological Chemistry".

    more info
  • SaxoCell – “living drug” Made in Saxony

    Press release / February 04, 2021

    Pharmazeutische Herstellung eines zellbasierten Medikaments im Reinraum
    © Fraunhofer IZI

    Saxony-based consortium comes out on top in the BMBF Clusters4Future initiative. In a digital press conference held by the German Federal Ministry of Education and Research (BMBF) on February 3, 2021, the SaxoCell research consortium was announced as one of the clusters selected for funding. The consortium comprises experts from the TU Dresden, Leipzig University, Chemnitz Hospital and the Fraunhofer Institute for Cell Therapy and Immunology. Over the next three years, the project partners will collaborate with partners from academia and industry to provide novel cell and gene therapies for previously incurable diseases.

    more info